



July 30, 2020
JCR Pharmaceuticals Co., Ltd.

Translation

Notice of Assignment of responsibility to Director

JCR Pharmaceuticals Co., Ltd. (TSE 4552; Chairman and President: Shin Ashida; “JCR”) announced today that changes assignment of responsibility to director effective from July 31, 2020 as follows.

1. Assignment of Responsibility to Director

Name	New Title	Current Title
Mathias Schmidt, PD, Ph.D.	Senior Executive Director In charge of International Strategy ArmaGen, Inc. CEO JCR USA, Inc. President and CEO	Senior Executive Director In charge of International Strategy ArmaGen, Inc. CEO

(Note) The above change will be subject to approval at the annual meeting and the board of directors of JCR USA, Inc. scheduled in July 31, 2020.

<Reference> About JCR USA.

Corporate name	JCR USA, Inc.
Location	Torrance, California, U.S.A
Business	Control and supervision of services of related to clinical trials contracted to CRO and coordination and consultation of clinical trials Research and development, import and export, shipping and warehousing of clinical trial material, reagents, their raw materials and such related materials
Date of establishment	January, 2018

[About JCR Pharmaceuticals]

JCR is a specialty pharma company engaged in the research, development, manufacturing and marketing of biopharmaceuticals and regenerative medicine with a focus on rare diseases. Its philosophy, “Contributing towards people’s healthcare through pharmaceutical products” drives JCR to create innovative pharmaceutical products as value-added treatment options for the under-served patient populations.

[Cautionary Statement Regarding Forward-Looking Statements]

This document contains forward-looking statements that are subject to known and unknown risks and uncertainties, many of which are outside our control. Forward-looking statements often contain words such as “believe,” “estimate,” “anticipate,” “intend,” “plan,” “will,” “would,” “target” and similar references to future periods. All forward-looking statements regarding our plans, outlook, strategy and future business, financial performance and financial condition are based on judgments derived from the information available to us at this time. Factors or events that could cause our actual results to be materially different from those expressed in our forward-looking statements include, but not limited to, a deterioration of economic conditions, a change in the legal or governmental system, a delay in launching a new product, impact on competitors’ pricing and product strategies, a decline in marketing capabilities relating to our products, manufacturing difficulties or delays, an infringement of our intellectual property rights , an adverse court decision in a significant lawsuit and regulatory actions.

This document involves information on pharmaceutical products (including those under development). However, it is not intended for advertising or providing medical advice. Furthermore, it is intended to provide information on our company and businesses and not to solicit investment in securities we issue.

Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the factors that could cause actual results to differ materially, even if new information becomes available in the future.

Investors & Media:

JCR Pharmaceuticals Co., Ltd.

Corporate Communications

ir-info@jcrpharm.co.jp

END

###